An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
Chung‐Feng Huang(Kaohsiung Medical University), Ming‐Lung Yu(National Sun Yat-sen University), Ming‐Jong Bair(Mackay Medical College), Chia‐Yen Dai(Kaohsiung Medical University), Rong‐Nan Chien(Chang Gung Memorial Hospital), Jee‐Fu Huang(Kaohsiung Medical University), Jia‐Horng Kao(National Taiwan University Hospital), Cheng‐Yuan Peng(China Medical University), Chun‐Han Cheng(Mackay Memorial Hospital), Yi‐Hsiang Huang(First Hospital of Lanzhou University), Chun‐Yen Lin(Chang Gung University), Pin‐Nan Cheng(National Cheng Kung University Hospital), Chao‐Hung Hung(Chang Gung University), Shih‐Jer Hsu(National Taiwan University Hospital), Tsai-Yuan Hsieh(Tri-Service General Hospital), Wan‐Long Chuang(Kaohsiung Medical University), Pei-Lun Lee(Chi Mei Medical Center), Jyh-Jou Chen(Chi Mei Medical Center)
Cited by 19
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364